Ivo N. Van Schaik

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 92 publications

Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Journal: The Cochrane database of systematic reviews
Published: August 11, 2026

The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

The Diagnostic Accuracy of the Second Revision of the European Academy of Neurology/Peripheral Nerve Society Guideline for Diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Journal: European journal of neurology
Published: March 09, 2026

Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 03, 2025

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.

CIDP With and Without Monoclonal Gammopathy of Undetermined Significance (MGUS): Comparison of Clinical Phenotype, Diagnostic Features, and Treatment Response.

Journal: Journal of the peripheral nervous system : JPNS
Published: September 12, 2025

Validity and Responsiveness of Balance Measurements Using Posturography in Patients With Immune-Mediated Neuropathies.

Validity and Responsiveness of Balance Measurements Using Posturography in Patients With Immune-Mediated Neuropathies.

Journal: Journal of the peripheral nervous system : JPNS
Published: March 28, 2025

Unique Nerve Tissue-Restricted T-Cell Clones in Chronic Inflammatory Demyelinating Polyneuropathy.

Unique Nerve Tissue-Restricted T-Cell Clones in Chronic Inflammatory Demyelinating Polyneuropathy.

Journal: Journal of the peripheral nervous system : JPNS
Published: October 30, 2024

Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 with disease activity and treatment response.

Type I interferon biomarker in idiopathic inflammatory myopathies: associations of Siglec-1 with disease activity and treatment response.

Journal: Rheumatology (Oxford, England)
Published: May 24, 2024

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

Journal: The Cochrane database of systematic reviews
Published: February 14, 2024

Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives.

Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives.

Journal: Therapeutics and clinical risk management
Published: November 13, 2023

Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy.

Proximity extension assay-based discovery of biomarkers for disease activity in chronic inflammatory demyelinating polyneuropathy.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: August 11, 2023

Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial.

Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial.

Journal: BMJ open
Published: July 10, 2023

Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy.

Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy.

Journal: Journal of neuroimmunology
Published: March 30, 2023
Showing 1-12 of 92

Last Updated: 09/26/2026